

# PLASYS300<sup>®</sup>, THE NEW COMPLEX FOR PROSTATE HEALTH

Inarejos-García, AM.<sup>a</sup>, Madrid, R.<sup>b</sup>, Jiménez, A.<sup>b</sup>, Morales, D. <sup>c</sup>, Prodanov, M.<sup>c</sup>

<sup>a</sup>Pharmactive Biotech Products S.L. Parque Científico de Madrid, Madrid, Spain. Phone: 911 123 848; e-mail: [aminarejos@pharmactive.eu](mailto:aminarejos@pharmactive.eu)

<sup>b</sup>Bioassays SL. Parque Científico de Madrid, Madrid, Spain

<sup>c</sup>Instituto de Investigación en Ciencias de la Alimentación (CIAL; CSIC-UAM, Madrid, Spain).

## INTRODUCTION

Benign prostatic hyperplasia (BPH) leads to obstructive urinary symptoms experienced to some extent by most men over 50 years old (Berry et al., 1984; Thorpe & Nea., 2003).

Test and diagnosis consist of a physical exam focused on the urinary tract, blood and urine analysis, and digital rectal exam (**Figure 1**). The pharmacotherapy treatments are via 5 $\alpha$ -reductase inhibitors (5-ARIs) or Alpha-blockers, but both treatments show several undesirable side effects (Robert et al., 2011; **Table 1**).


Plasys300<sup>®</sup> is a natural complex enriched in phytosterols, chiefly  $\beta$ -sitosterol and essential amino-acids with proven effectiveness in ameliorating prostate discomfort symptoms: diminish IPSS score, urinary flow rate, irritating (itching) and obstructive symptoms (Berges et al., 1995; Dutkiewicz, 1996, Elist, 2006).

## OBJECTIVES

The main objective of this work was to test the effect in vitro of the bioactive components of Plasys300<sup>®</sup> in human cells from prostatic adenocarcinoma, PC3 cell line, and to evaluate cell viability and proliferation.

**Table 1.** FDA-Approved drugs to treat BPH

Alpha antagonists	Side effects
Alfuzosin	Retrograde ejaculation
Doxazosin	Erectile dysfunction
Silodosin	Asthemia
Tamsulosin	Dizziness
Terazosin	Orthostatic hypotension
	Nasal congestion
5-alpha-Reductase Inhibitors	Side effects
Dutasteride	Reduced libido
	Erectile dysfunction
Finasteride	Decreased ejaculate volume
	Breast tenderness



**Figure 1.** Digital Rectal Exam (DRE)

Alan Hoofing  
(Illustrator)

## METHODOLOGY

Sterols (non-saponified fractions) from Plasys300<sup>®</sup> samples were extracted following the procedure described by Gil-Ramirez et al. (2013). Non-saponified fractions were prepared at 12 mg/mL in a chloroform:methanol (2:1 v/v) solution including hexadecane as internal standard and submitted to GC-MS-FID analysis according to Teichmann et al. (2007).


Proliferation assays were performed in PC-3 cultures using increasing concentrations of Plasys300<sup>®</sup> (saponified or non-saponified fractions). MTT-assay (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium-bromide (Sigma-Aldrich), was performed according to the manufacturer's instructions. Statistical analysis was performed by the unpaired Student's t-test. The significance level was set as P=0.05.

## RESULTS


Phytosterols act as 5-alpha-Reductase Inhibitors, chiefly  $\beta$ -sitosterol (**Figure 2**), which is effective in relieving BPH symptoms (Berges et al., 2000).

Sterol fraction of Plasys300<sup>®</sup> induced anti-proliferation of human prostatic (PC-3) cells in a dose-dependent manner. At 10  $\mu$ g/mL it inhibited cell proliferation by 50% whereas at its highest concentration, 50  $\mu$ g/mL the inhibition held up at 65%

**Figure 2.** Gas-FID chromatogram of Plasys300<sup>®</sup>



**Figure 3.** Effects of Plasys300<sup>®</sup> on Cell Proliferation



## CONCLUSIONS

The fraction corresponding to phytosterols in Plasys300<sup>®</sup> has a significant effect on cell viability at concentrations of 10  $\mu$ g / mL and above.

The slope of reduction observed from this concentration suggests that Plasys300<sup>®</sup> is not cytotoxic but has an antiproliferative effect in a prostatic cancer cell line.

## Bibliography

- Berry, et al., 1984. Journal of Urology. 132,474-479.
- Thorpe & Neal, 2003. The Lancet, 361, 1359-1367.
- Robert et al., 2004. Journal of Managed Care Pharmacy, 10, 412-422.
- Berges et al., 1995. The Lancet, 345, 1529-1532
- Dutkiewicz et al., 1996. International Urology and Nephrology 28, 211-214 (1996)
- Elist, 2006. Urology, 67, 60-63.
- Gil-Ramirez et al., 2013. Innovative Food Science and Emerging Technologies 18, 101-107
- Teichmann et al., 2007. Lwt-Food Science and Technology, 40, 815-822
- Berges et al., 2000. BJU International, 85, 842±846

PHARM  ACTIVE  
BIOTECH PRODUCTS  
*a natural difference*